Table of Content

Scope and Methodology
1.1. Research Methodology
1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary
3.1. Market Snippet by Drug Class
3.2. Market Snippet by Route of Administration
3.3. Market Snippet by End Users
3.4. Market Snippet by Region

4. Market Dynamics
4.1. Market impacting factors
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Impact analysis

5. Industry Analysis
5.1. Porter’s five forces analysis
5.2. Value chain analysis
5.3. Patent Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives

7. By Drug Class
7.1. Introduction
7.1.1. Market size analysis, and y-o-y growth analysis (%), By Drug Class Segment
7.1.2. Market attractiveness index, By Drug Class Segment
7.2. Anti-Psychotics *
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
7.3. Benzodiazepines
7.4. Others

8. By Route of Administration
8.1. Introduction
8.1.1. Market size analysis, and y-o-y growth analysis (%), By Route of Administration Segment
8.1.2. Market attractiveness index, By Route of Administration Segment
8.2. Oral *
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
8.3. Intramuscular
8.4. Others

9. By End Users
9.1. Introduction
9.1.1. Market size analysis, and y-o-y growth analysis (%), By End Users Segment
9.1.2. Market attractiveness index, By End Users Segment
9.2. Hospitals & Ambulatory Surgical Centers *
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
9.3. Psychiatric Care Facilities
9.4. Others

10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key region-specific dynamics
10.2.2.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.2.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
10.2.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.2.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.2.5. U.S.
10.2.2.6. Canada
10.2.2.7. Mexico
10.3. South America
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
10.3.7.1. Brazil
10.3.7.2. Argentina
10.3.7.3. Rest of South America
10.4. Europe
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
10.4.7.1. Germany
10.4.7.2. U.K.
10.4.7.3. France
10.4.7.4. Spain
10.4.7.5. Italy
10.4.7.6. Rest of Europe
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. Australia
10.5.7.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics

11. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

12. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

13. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

14. Competitive Landscape
14.1. Competitive scenario
14.2. Competitor strategy analysis
14.3. Market positioning/share analysis
14.4. Mergers and acquisitions analysis

15. Company Profiles
15.1. Bristol-Myers Squibb Company*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Key Highlights
15.1.4. Financial Overview
15.2. Eli Lilly and Company
15.3. GlaxoSmithKline plc
15.4. H. Lundbeck A/S
15.5. Janssen Biotech, Inc. (Johnson & Johnson)
15.6. Ono Pharmaceutical Co., Ltd.
15.7. Otsuka Holdings Co., Ltd.
15.8. Pfizer Inc.
15.9. Mylan NV
15.10. Teva Pharmaceutical Industries Ltd
*List not Exhaustive*

16. DataM
16.1. Appendix
16.2. About us and services
16.3. Contact us